Previous 10 | Next 10 |
Shares of Finch Therapeutics (FNCH +10.1%) are on the rise today after a director of the company and venture capital investor bought additional shares. Nicolas Haft, managing director of OMX Ventures, bought 63,850 shares at $10.18 on Dec. 20 according to an SEC filing. Following the transact...
Gainers: Del Taco Restaurants (NASDAQ:TACO) +66%. Insignia Systems (NASDAQ:ISIG) +64%. Adicet Bio (NASDAQ:ACET) +37%. Cloopen Group (NYSE:RAAS) +24%. eFFECTOR Therapeutics (NASDAQ:EFTR) +20%. Recruiter (NASDAQ:RCRT) +21%. Edgewise Therapeutics (NASDAQ:EWTX) +21%. Liberty TripAdvisor (NASDAQ:L...
The shares of Seres Therapeutics (MCRB +18.6%) have reached the highest level in more than four months after the company announced the enrollment of the first patient in an early-stage study for microbiome therapy SER-155 in graft-versus-host disease ((GvHD)). Conducted in partnership with Me...
Seth Klarman’s 13F portfolio value decreased from $12.33B to $10.88B this quarter. Baupost Group increased Liberty SiriusXM, Theravance Biopharma, and Joby Aviation while decreasing eBay, Willis Towers Watson, International Flavors & Fragrances, and PG&E. The portfo...
SOMERVILLE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel ...
Finch Therapeutics (NASDAQ:FNCH): Q3 GAAP EPS of -$0.21 beats by $0.07. Revenue of $11.34M, compared to $1.77M a year ago. Cash and cash equivalents as of September 30, 2021 was $149.2M Press Release For further details see: Finch Therapeutics EPS beats by $0.07
New positive topline data from 132-participant PRISM-EXT Phase 2 open-label trial of CP101 in recurrent C. difficile infection (CDI) show 80.3% sustained clinical cure rate through 8 weeks, with a similar rate maintained through 24 weeks New data presented at ACG annual meeting ...
Zain Kassam, MD, MPH to step down as Chief Medical Officer (CMO) and will serve as a special advisor to the company Debra Silberg, MD, PhD to transition from clinical advisor to interim CMO SOMERVILLE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, ...
New data from 132-participant PRISM-EXT Phase 2 open-label trial show 80.3% sustained clinical cure rate through 8 weeks, with a similar rate maintained through 24 weeks and a safety profile consistent with previously reported data Aggregated 88.2% sustained clinical cure ra...
New data from PRISM3 Phase 2 trial show CP101 demonstrated statistically significant efficacy for prevention of recurrent C. difficile infection and a favorable safety profile through 24 weeks Additional PRISM3 microbiome data show CP101 engraftment leads to an increase in int...
News, Short Squeeze, Breakout and More Instantly...
Finch Therapeutics Group Inc. Company Name:
FNCH Stock Symbol:
NASDAQ Market:
Finch Therapeutics Group Inc. Website:
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 8.6% to $0.0384 on volume of 89,961,220 shares Nuburu Inc. (BURU) rose 29.4% to $0.207 on volume of 85,213,370 shares Novo Integrated Sciences Inc. (NVOS) rose 139.5% to $1.08 on volume ...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 5.3% to $0.0839 on volume of 148,968,464 shares Netcapital Inc. (NCPL) rose 66.0% to $0.2901 on volume of 111,713,040 shares Cue Health Inc. (HLTH) rose 33.6% to $0.126 on volume of 99,7...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...